10-K: NovoCure 2025 Annual Report: Revenue Growth Amid R&D Investment

NovoCure Limited reports 8% revenue growth to $655.4 million in 2025, driven by Optune Gio adoption and new product launches, despite continued operating losses and increased R&D spending.

Summary

• Net revenues increased by 8% to $655.4 million in 2025 from $605.2 million in 2024, primarily due to growth in international markets and Optune Lua sales.
• The company reported an operating loss of $(153.8) million in 2025, an improvement from $(170.5) million in 2024.
• Net loss for 2025 was $(136.2) million, compared to $(168.6) million in 2024.
• Adjusted EBITDA decreased significantly to $(34.3) million in 2025 from $0.8 million in 2024, mainly due to increased costs for new indications.
• Cash, cash equivalents, and short-term investments decreased by $512.2 million to $447.7 million at December 31, 2025, largely due to the repayment of a $560.9 million convertible note.
• Optune Pax received FDA approval for locally advanced pancreatic cancer in February 2026.
• Final data from the Phase 3 METIS trial for brain metastases from NSCLC showed a 28% lower risk of intracranial progression with TTFields therapy (median TTIP 15.0 months vs. 7.5 months for BSC alone).
• A Premarket Approval (PMA) application for Optune Mya (for brain metastases from NSCLC) was submitted in December 2025 and is under substantive FDA review.
• Enrollment for the TRIDENT Phase 3 trial in GBM was completed in 2024, with topline data anticipated in Q2 2026.
• The KEYNOTE D58 Phase 3 trial in GBM is open and enrolling, with completion anticipated by the end of 2026.
• Enrollment for the PANOVA-4 Phase 2 trial in metastatic pancreatic cancer was completed in 2024, with topline data anticipated in Q1 2026.
• The company repaid $560.9 million of 0% Convertible Senior Notes at maturity in November 2025.
• The Tranche B Loan of $100.0 million from the senior secured credit facility was drawn in September 2025, bringing the total borrowed to $200.0 million; options for Tranche C and D loans were not exercised.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed filing. While revenue growth and new product approvals are positive, the significant decline in Adjusted EBITDA, reduced gross margin, and substantial cash burn indicate ongoing financial challenges and increased operational costs that outweigh the positive clinical and regulatory advancements in the short term.

Positives

• Net revenues increased by 8% to $655.4 million in 2025, demonstrating continued commercial adoption of products.
• Net loss decreased to $(136.2) million in 2025 from $(168.6) million in 2024, indicating a reduction in losses.
• FDA approval for Optune Pax for locally advanced pancreatic cancer in February 2026 expands the addressable market for TTFields therapy.
• Positive final data from the Phase 3 METIS trial for brain metastases from NSCLC showed a 28% lower risk of intracranial progression and extended median time to intracranial progression (15.0 months vs. 7.5 months for BSC alone).
• The PMA for Optune Mya (brain metastases from NSCLC) has been accepted by the FDA and is under substantive review, indicating progress towards another potential approval.
• Continued growth in active patients for Optune Gio in international markets (Germany, France, Japan, other international) highlights successful market penetration.
• Successful repayment of $560.9 million convertible notes at maturity strengthens the balance sheet by reducing debt obligations.
• Increased production capacity in Mexico and Ireland is being added to enhance supply chain resilience and optimize cost structure.

Negatives

• The company continues to incur substantial operating losses, with an accumulated deficit of $1,290.4 million as of December 31, 2025.
• Adjusted EBITDA decreased significantly to $(34.3) million in 2025 from $0.8 million in 2024, primarily due to increasing costs for new indications, indicating a decline in operational profitability.
• Cash, cash equivalents, and short-term investments decreased by $512.2 million in 2025, reflecting significant cash utilization.
• Gross margin decreased to 75% in 2025 from 77% in 2024, attributed to reduced prior period claims benefits, higher tariffs, and increased array costs.
• Cost of revenues increased by 22% to $166.9 million, driven by Optune Gio active patient growth, new array rollout, NSCLC launch, higher tariffs, and sales to Zai.
• A $3.2 million inventory obsolescence provision for Optune Lua arrays was recognized in 2025.
• Research, development, and clinical studies expenses increased by 7% to $224.5 million, reflecting ongoing high investment in pipeline development.
• The company did not exercise its options to draw Tranche C and D loans from the senior secured credit facility, potentially limiting future financing flexibility.
• The Phase 3 INNOVATE-3 trial for platinum-resistant ovarian cancer did not meet its primary endpoint of overall survival.

Risks

• Business and prospects depend heavily on Optune Gio, Optune Lua, and Optune Pax; inability to increase sales or obtain further regulatory approvals for additional indications will materially harm the business.
• History of incurring substantial operating losses and expectation to continue incurring significant costs associated with commercializing products and R&D.
• Clinical studies could be delayed or adversely affected by difficulties in patient enrollment, problems with third-party providers, or negative/inconclusive results.
• Difficulty in achieving market acceptance of products by healthcare professionals, patients, and third-party payers due to new technology, side effects (skin irritation), continuous use requirements, and cost.
• Failure to secure and maintain adequate coverage and reimbursement from third-party payers, including governmental agencies like Medicare, could reduce revenues.
• Dependence on single-source suppliers for some components, the loss of which could prevent or delay shipments or clinical studies.
• Quality control problems with respect to materials supplied by third-party suppliers could harm reputation and financial results.
• Intense competition from numerous, well-capitalized competitors in the oncology market, potentially leading to lower prices or market share loss.
• Termination of relationships with key employees, consultants, and advisors may prevent successful business operation.
• Product liability suits, whether meritorious or not, could result in expensive litigation, substantial damages, and increased insurance rates.
• Fluctuations in global economic, political, industry, and environmental conditions (e.g., conflict in Israel affecting research facilities and suppliers, U.S. tariff rate changes) may adversely affect business.
• Increasing dependence on information technology systems and vulnerability to cybersecurity breaches and data leakage, subject to privacy and data security laws (HIPAA, GDPR).
• Extensive post-marketing regulation by the FDA and comparable authorities in other jurisdictions, which could impact sales and marketing and incur significant compliance costs.
• Modifications to products may require new regulatory approvals, which may not be granted or may cause delays, requiring cessation of promotion or product recalls.
• Risk of fines, penalties, or injunctions if determined to be promoting the use of products for unapproved or off-label uses.
• Adverse determinations by taxing or other governmental authorities or changes in tax laws, rates, or status could increase the tax burden.
• Subject to environmental laws and regulations that could be costly to comply with or result in costly liabilities, including those related to PFAS and lead content in arrays.
• Safety issues concerning lithium-ion batteries used in products could lead to accidents, lawsuits, product recalls, or operational disruptions.
• Failure to maintain, develop, protect, defend, or enforce intellectual property rights, including patent expiration (some U.S. patents expiring between 2025 and 2041), could allow competitors to develop competing therapies.
• Intellectual property litigation and disputes may cause substantial costs, divert management attention, and harm reputation.
• The market price for ordinary shares may be volatile due to various factors.
• Incorporation under the laws of Jersey may not provide the same level of legal certainty and transparency as incorporation in a U.S. state.
• U.S. shareholders may not be able to enforce civil liabilities against the company.
• Significant amount of debt ($200.0 million borrowed under the Facility) and the ability to borrow additional debt in the future could adversely affect financial condition and operational flexibility.

Future Outlook

The company anticipates continued strategic expansion into additional geographic markets and indications, pending regulatory approval. It expects to continue significant expenditures on sales, marketing, and research and development, particularly for new indications. Gross margins are expected to be impacted by the launch of Optune Pax while seeking broad reimbursement, offset by anticipated decreases in array costs as the supply chain is optimized. The global tariff environment is expected to remain volatile, and the company is actively working to mitigate potential impacts. The company aims to prioritize growth and maintain financial health as it positions itself for future profitability.

Management Comments

• "We are committed to investing strategically to maximize the growth potential of the TTFields therapy platform."
• "We are prioritizing clinical programs which have the greatest value potential in solid tumors where TTFields therapy has established efficacy and an unmet clinical need for biophysical treatment exists, including glioblastoma, pancreatic cancer and non-small cell lung cancer."
• "We believe we have largely built out the structure to support a global multi-indication oncology company and will look to moderate general and administrative expense growth to achieve profitability."
• "We intend to take actions that prioritize growth and maintain financial health as we position our company for future profitability."

Industry Context

StockSavvy.ai notes that NovoCure operates in the highly competitive oncology and medical device markets, characterized by rapid change and significant R&D investment from large, well-capitalized companies. The company's focus on Tumor Treating Fields (TTFields) therapy represents a novel, non-systemic approach, which positions it uniquely against traditional radiation, chemotherapy, and immunotherapy. The expansion into new indications like NSCLC brain metastases and pancreatic cancer aligns with broader industry efforts to address aggressive cancers with high unmet needs. However, the challenge of securing broad market acceptance and reimbursement for new technologies remains a significant hurdle, common across the innovative medical device sector.

Comparison to Industry Standards

• The median overall survival of 13.2 months for metastatic NSCLC patients treated with Optune Lua and standard therapies (vs. 9.9 months for standard therapies alone) in the LUNAR trial compares favorably to historical benchmarks for second-line NSCLC treatments, indicating a meaningful clinical benefit.
• The median overall survival of 16.2 months for locally advanced pancreatic cancer patients treated with Optune Pax and gemcitabine/nab-paclitaxel (vs. 14.2 months for chemotherapy alone) in the PANOVA-3 trial represents a clinically relevant improvement in a highly lethal cancer, where incremental gains are significant.
• The 15.0 months median time to intracranial progression for NSCLC brain metastases patients treated with TTFields therapy and BSC (vs. 7.5 months for BSC alone) in the METIS trial demonstrates a substantial delay in progression, which is a critical outcome in managing brain metastases.
• The company's gross margin of 75% in 2025 is generally strong for a medical device company, though the 2% decrease from 2024 highlights cost pressures from new product launches and tariffs.
• The accumulated deficit of $1.29 billion and continued operating losses are typical for a biotechnology company heavily investing in R&D and market expansion for novel therapies, but indicate a need for sustained revenue growth to achieve profitability.

Management Changes

Corporate Governance

Legal Proceedings

• The company is involved in various legal proceedings, claims, investigations, and litigation that arise in the ordinary course of business. Management believes the ultimate disposition of these matters will not materially affect its consolidated financial position or results of operations.
• The company is currently under examination by tax authorities in Israel and Germany.
• Additional tax years within the period from 2019 to 2024 remain subject to examination by various tax authorities.

Related Party Transactions

• License and Collaboration Agreement with Zai Lab (Shanghai) Co., Ltd. (Zai) in 2018, granting Zai exclusive rights to commercialize products in Greater China. Zai pays tiered royalties and purchases licensed products at fully burdened manufacturing cost.
• Clinical collaboration between Novocure and MSD (a tradename of Merck & Co., Inc.) for the randomized, double blind, placebo controlled Phase 3 KEYNOTE D58 clinical trial in GBM.
• Clinical collaboration between Novocure and Roche for the Phase 2 PANOVA-4 trial in metastatic pancreatic cancer.

Stakeholder Impact

• Shareholders: Potential for long-term value creation through new product approvals and market expansion, but current operating losses, decreased Adjusted EBITDA, and significant cash burn pose short-term financial risks. Share price volatility is a noted risk.
• Employees: A restructuring in November 2023 led to a reduction of approximately 200 employees (13% of the workforce). New incentive plans (2024 Omnibus Incentive Plan) aim to attract and retain talent, but job security concerns may persist.
• Patients: New FDA approvals (Optune Pax, potential Optune Mya) offer new treatment options for aggressive cancers like pancreatic cancer and NSCLC brain metastases, potentially extending survival and improving quality of life.
• Healthcare Providers: Requires certification training to prescribe products. Reimbursement for physician services related to TTFields therapy is a concern due to the absence of specific CPT codes, which could affect prescription rates.
• Suppliers: Dependence on single-source suppliers creates supply chain risks, but the company is working to diversify its supply chain and increase stock levels to mitigate potential disruptions.
• Payers: Ongoing efforts to secure and maintain adequate coverage and reimbursement for new and existing products, with challenges in obtaining reasonable rates and potential for increased cost-sharing burden for patients.

Next Steps

• Advance clinical and product development programs to extend overall survival in aggressive forms of cancer.
• Pursue regulatory approval to market TTFields therapy devices in new indications, such as brain metastases from NSCLC (Optune Mya).
• Actively evaluate opportunities to expand access to Optune Gio, Optune Lua, and Optune Pax in additional international markets.
• Actively pursue coverage policies with payers to expand access to Optune Lua and Optune Pax.
• Anticipate topline data from the TRIDENT Phase 3 trial in GBM in the second quarter of 2026.
• Anticipate completing enrollment for the KEYNOTE D58 Phase 3 trial in GBM by the end of 2026.
• Anticipate topline data from the PANOVA-4 Phase 2 trial in pancreatic cancer in the first quarter of 2026.
• Continue to conduct research to further advance the scientific evidence supporting the use of TTFields therapy and gather additional information about its optimal use.
• Continue to advance products to optimize TTFields therapy through engineering efforts, focusing on field generator and array enhancements, and development of software applications.
• Continue to make significant expenditures associated with selling and marketing products, prioritizing launch readiness for the anticipated approval of TTFields therapy for pancreatic cancer outside the United States and for future new indications.
• Focus on opportunities to increase efficiencies and scale within the supply chain, including evaluating new materials, manufacturers, structures, and processes.
• Monitor proposals and other developments that would materially impact the tax and tariff burden and effective tax rate.
• Continue to recruit, hire, train, and retain qualified scientific, regulatory, technical, and managerial personnel.

Key Dates

Recommendation

The company demonstrates strong clinical progress with new FDA approvals and positive trial data for significant indications like pancreatic cancer and NSCLC brain metastases, which are crucial for future growth. However, the continued operating losses, decreased Adjusted EBITDA, and substantial reduction in cash reserves due to debt repayment and ongoing R&D investments present near-term financial headwinds. The decline in gross margin also signals cost pressures. While the long-term potential of TTFields therapy is compelling, the current financial performance and the need to secure widespread reimbursement for new products suggest a 'Hold' recommendation until there is clearer evidence of sustainable profitability and improved cash flow generation.

Keywords

Tumor Treating Fields, TTFields, Oncology, Glioblastoma, GBM, Non-Small Cell Lung Cancer, NSCLC, Malignant Pleural Mesothelioma, MPM, Pancreatic Cancer, Brain Metastases, Optune Gio, Optune Lua, Optune Pax, Optune Mya, Medical Device, Cancer Treatment, FDA Approval, Clinical Trials, SEC Filing, Financial Report, Biotechnology, Healthcare